SECTION 1. IDENTIFICATION

Product name : POLIVY(R) Vials (30 mg & 140 mg)
Product code : RO554-1077/F02
Common name(s), synon-ym(s) of the substance : Polatuzumab Vedotin Lyophilized Vials Anti-CD79b-vc-MMAE with excipients lyophilized

Manufacturer or supplier's details
Company name of supplier : Genentech, Inc.
Address : 1 DNA Way
South San Francisco, CA 94080
USA
Telephone : 001-(650) 225-1000
E-mail address : info.sds@roche.com
Emergency telephone : US Chemtrec phone (800)-424-9300

Recommended use of the chemical and restrictions on use
Recommended use : Formulated pharmaceutical active substance
Restrictions on use : For professional users only.

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)
Combustible dust
Acute toxicity (Oral) : Category 2
Acute toxicity (Inhalation) : Category 3
Germ cell mutagenicity : Category 1B
Reproductive toxicity : Category 1B

GHS label elements
Hazard pictograms : 

Signal Word : Danger
Hazard Statements : May form combustible dust concentrations in air.
H300 Fatal if swallowed.
H331 Toxic if inhaled.
H340 May cause genetic defects.
H360D May damage the unborn child.

Precautionary Statements:
Prevention:
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P261 Avoid breathing dust.
P264 Wash skin thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P271 Use only outdoors or in a well-ventilated area.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:
P301 + P310 + P330 IF SWALLOWED: Immediately call a POISON CENTER/ doctor. Rinse mouth.
P304 + P340 + P311 IF INHALED: Remove person to fresh air and keep comfortable for breathing. Call a POISON CENTER/ doctor.
P308 + P313 IF exposed or concerned: Get medical advice/ attention.

Storage:
P403 + P233 Store in a well-ventilated place. Keep container tightly closed.
P405 Store locked up.

Disposal:
P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards
None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture: Mixture

<table>
<thead>
<tr>
<th>Components</th>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Polatuzumab vedotin</td>
<td>1313206-42-6</td>
<td>31.2</td>
<td></td>
</tr>
<tr>
<td>.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl</td>
<td>57-50-1</td>
<td>64.2</td>
<td></td>
</tr>
<tr>
<td>Butanedioic acid, sodium salt (1:2)</td>
<td>150-90-3</td>
<td>2.7</td>
<td></td>
</tr>
<tr>
<td>Sorbitan, monododecanoate, poly(oxy-1,2-ethanediyl) derivs.</td>
<td>9005-64-5</td>
<td>1.9</td>
<td></td>
</tr>
</tbody>
</table>

SECTION 4. FIRST AID MEASURES

General advice: Move out of dangerous area. Consult a physician.
Show this material safety data sheet to the doctor in attendance.
Symptoms of poisoning may appear several hours later.
Do not leave the victim unattended.

If inhaled: Call a physician or poison control center immediately.
Move to fresh air.
If unconscious, place in recovery position and seek medical advice.

In case of skin contact: If on skin, rinse well with water.

In case of eye contact: Immediately flush eye(s) with plenty of water.
Remove contact lenses.
Protect unharmed eye.
Keep eye wide open while rinsing.
If eye irritation persists, consult a specialist.

If swallowed: Keep respiratory tract clear.
Do not give milk or alcoholic beverages.
Never give anything by mouth to an unconscious person.
If symptoms persist, call a physician.
Take victim immediately to hospital.
Rinse mouth with water.

Most important symptoms and effects, both acute and delayed: Fatal if swallowed.
Toxic if inhaled.
May cause genetic defects.
May damage the unborn child.

Notes to physician: The first aid procedure should be established in consultation with the doctor responsible for industrial medicine.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.

Unsuitable extinguishing media: High volume water jet

Specific hazards during fire fighting: Do not allow run-off from fire fighting to enter drains or water courses.

Hazardous combustion products: In case of fire hazardous decomposition products may be produced such as:
Carbon monoxide
Nitrogen oxides (NOx)
Carbon oxides

Further information: Collect contaminated fire extinguishing water separately. This must not be discharged into drains.
Fire residues and contaminated fire extinguishing water must be disposed of in accordance with local regulations.

Special protective equipment: Wear self-contained breathing apparatus for firefighting if
SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures:
- Prevent any exposure
- Use personal protective equipment.
- Avoid dust formation.
- Avoid breathing dust.
- Ensure adequate ventilation.
- Evacuate personnel to safe areas.

Environmental precautions:
- Prevent product from entering drains.
- Prevent further leakage or spillage if safe to do so.
- If the product contaminates rivers and lakes or drains inform respective authorities.

Methods and materials for containment and cleaning up:
- Keep in suitable, closed containers for disposal.

SECTION 7. HANDLING AND STORAGE

Advice on protection against fire and explosion:
- Avoid dust formation.
- Provide appropriate exhaust ventilation at places where dust is formed.

Advice on safe handling:
- Avoid formation of respirable particles.
- Do not breathe vapors/dust.
- Avoid exposure - obtain special instructions before use.
- Avoid contact with skin and eyes.
- For personal protection see section 8.
- Smoking, eating and drinking should be prohibited in the application area.
- Provide sufficient air exchange and/or exhaust in work rooms.
- Dispose of rinse water in accordance with local and national regulations.

Conditions for safe storage:
- Prevent unauthorized access.
- Keep container tightly closed in a dry and well-ventilated place.
- Containers which are opened must be carefully resealed and kept upright to prevent leakage.
- Observe label precautions.
- Electrical installations / working materials must comply with the technological safety standards.

Further information on storage conditions:
- See label, package insert or internal guidelines

Storage temperature:
- 2 °C to 8 °C
- Protected from heat and light
- Protect from moisture.

Further information on storage stability:
- Keep in a dry place.
- No decomposition if stored and applied as directed.
### SAFETY DATA SHEET

**POLIVY(R) Vials (30 mg & 140 mg)**

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date:</th>
<th>Date of last issue:</th>
<th>Date of first issue:</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.0</td>
<td>11-25-2022</td>
<td>01-23-2020</td>
<td>06-10-2017</td>
</tr>
</tbody>
</table>

Packaging material: Suitable material: Vials, glass

---

### SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

**Ingredients with workplace control parameters**

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl</td>
<td>57-50-1</td>
<td>TWA</td>
<td>10 mg/m^3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (Respirable)</td>
<td>5 mg/m^3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (total)</td>
<td>10 mg/m^3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (total dust)</td>
<td>15 mg/m^3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (respirable fraction)</td>
<td>5 mg/m^3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (Total dust)</td>
<td>15 mg/m^3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (respirable dust fraction)</td>
<td>5 mg/m^3</td>
</tr>
<tr>
<td>Polatuzumab vedotin</td>
<td>1313206-42-6</td>
<td>IOEL</td>
<td>0.00005 mg/m^3</td>
</tr>
</tbody>
</table>

**Engineering measures**: No data available

**Personal protective equipment**

**Respiratory protection**: In the case of dust or aerosol formation use respirator with an approved filter. Effective dust mask

**Hand protection**

- **In case of contact through splashing:**
  - Material: Nitrile rubber
  - Break through time: > 30 min
  - Glove thickness: > 0.11 mm

- **In case of full contact:**
  - Material: butyl-rubber
  - Break through time: > 480 min
  - Glove thickness: > 0.4 mm

**Remarks**: Wear appropriate protective gloves to prevent skin contact. Replace torn or punctured gloves promptly.

**Eye protection**: Eye wash bottle with pure water

Tightly fitting safety goggles
Skin and body protection: Dust impervious protective suit
Choose body protection according to the amount and concentration of the dangerous substance at the workplace.

Protective measures: Instruction of employees mandatory

Hygiene measures: Avoid contact with skin, eyes and clothing. When using do not eat or drink. When using do not smoke. Wash hands before breaks and immediately after handling the product.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance: powder, (lyophilized)

Color: white, off-white

Odor: Not applicable

Odor Threshold: Not applicable

pH: Not applicable

Melting point/range: No data available

Boiling point/boiling range: No data available

Flash point: does not flash

Evaporation rate: No data available

Self-ignition: No data available

Upper explosion limit / Upper flammability limit: No data available

Lower explosion limit / Lower flammability limit: No data available

Vapor pressure: No data available

Relative vapor density: Not applicable

Relative density: No data available

Solubility(ies):
Water solubility: soluble

Solubility in other solvents: No data available
### SECTION 10. STABILITY AND REACTIVITY

**Reactivity**
No dangerous reaction known under conditions of normal use.

**Chemical stability**
Stable under normal conditions.

Proteins are temperature-sensitive; the thermal denaturation has an impact on quality but does not affect Plant and Process Safety; during decomposition no flammable gas, no organic peroxide and no oxidising substances are created.

**Possibility of hazardous reactions**
No decomposition if stored and applied as directed. Dust may form explosive mixture in air.

**Incompatible materials**
No data available

**Hazardous decomposition products**
No data available

### SECTION 11. TOXICOLOGICAL INFORMATION

**Acute toxicity**
Fatal if swallowed.
Toxic if inhaled.

**Product:**

- **Acute oral toxicity**: Acute toxicity estimate: 32.05 mg/kg
  Method: Calculation method

- **Acute inhalation toxicity**: Acute toxicity estimate: 0.5128 mg/l
  Exposure time: 4 h
  Test atmosphere: dust/mist
  Method: Calculation method

**Components:**

- **.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:**
  Acute oral toxicity: LD50 Oral (Rat): 29,700 mg/kg

**Polatuzumab vedotin:**
**Acute oral toxicity**: LD50 (Rat): \(\geq 10\) mg/kg
   Method: Expert judgment

**Acute inhalation toxicity**: LC50 (Rat): \(\geq 0.16\) mg/l
   Exposure time: 4 h
   Test atmosphere: dust/mist
   Method: Expert judgment

**Acute toxicity (other routes of administration)**: LD50 (Rat): \(>0.1 < 0.2\) mg/kg
   Application Route: i.v.
   The value is given in analogy to the following substances:
   Monomethyl Auristatin E (MMAE)

   LD50 (Mouse): \(1-2\) mg/kg
   Application Route: i.v.
   The value is given in analogy to the following substances:
   Monomethyl Auristatin E (MMAE)

**Skin corrosion/irritation**: Not classified based on available information.

**Serious eye damage/eye irritation**: Not classified based on available information.

**Respiratory or skin sensitization**

**Skin sensitization**: Not classified based on available information.

**Respiratory sensitization**: Not classified based on available information.

**Germ cell mutagenicity**: May cause genetic defects.

**Components**: 

\(\alpha\)-D-Glucopyranoside, \(\beta\)-D-fructofuranosyl: 

Genotoxicity in vitro: Test Type: In vitro mammalian cell gene mutation test
   Result: negative

**Polatuzumab vedotin**: 

Germ cell mutagenicity - Assessment: In vivo tests showed mutagenic effects
   The value is given in analogy to the following substances:
   Monomethyl Auristatin E (MMAE)

**Carcinogenicity**: Not classified based on available information.

**Components**: 

\(\alpha\)-D-Glucopyranoside, \(\beta\)-D-fructofuranosyl: 

Remarks: No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.
SAFETY DATA SHEET

POLIVY(R) Vials (30 mg & 140 mg)

Version 2.0
Revision Date: 11-25-2022
Date of last issue: 01-23-2020
Date of first issue: 06-10-2017

IARC
No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

OSHA
No component of this product present at levels greater than or equal to 0.1% is on OSHA’s list of regulated carcinogens.

NTP
No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

Reproductive toxicity
May damage the unborn child.

Components:

Polatuzumab vedotin:

Effects on fetal development: Species: Rat
Result: Teratogenicity and developmental toxicity
The value is given in analogy to the following substances:
Monomethyl Auristatin E (MMAE)

Reproductive toxicity - Assessment:
May damage the unborn child., Presumed human reproductive toxicant
The value is given in analogy to the following substances:
Monomethyl Auristatin E (MMAE)

STOT-single exposure
Not classified based on available information.

Components:

.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:
Assessment: The substance or mixture is not classified as specific target organ toxicant, single exposure.

STOT-repeated exposure
Not classified based on available information.

Components:

.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:
Assessment: The substance or mixture is not classified as specific target organ toxicant, repeated exposure.

Repeated dose toxicity

Components:

Polatuzumab vedotin:
Species: Rat
Application Route: i.v.
Exposure time: 3 w
Remarks: Subacute toxicity
Species: Rat
### POLIVY(R) Vials (30 mg & 140 mg)

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date:</th>
<th>Date of last issue:</th>
<th>Date of first issue:</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.0</td>
<td>11-25-2022</td>
<td>01-23-2020</td>
<td>06-10-2017</td>
</tr>
</tbody>
</table>

- **STD10**: 10 mg/kg/w
- **Application Route**: i.v.
- **Exposure time**: 3 w
- **Remarks**: Subacute toxicity

- **Species**: Rat
- **NOEL**: 0.097 mg/kg/w
- **Application Route**: i.v.
- **Exposure time**: 28 d
- **Remarks**: Subacute toxicity

The value is given in analogy to the following substances: Monomethyl Auristatin E (MMAE)

**Aspiration toxicity**
Not classified based on available information.

**Components:**

- `.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl`
  - No data available

**Further information**

**Components:**

- `.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl`
  - Remarks: Health injuries are not known or expected under normal use.

### SECTION 12. ECOLOGICAL INFORMATION

**Ecotoxicity**

**Components:**

- `.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl`

**Ecotoxicology Assessment**

- **Acute aquatic toxicity**: This product has no known ecotoxicological effects.
- **Chronic aquatic toxicity**: This product has no known ecotoxicological effects.
- **Toxicity Data on Soil**: Not expected to adsorb on soil.
- **Other organisms relevant to the environment**: No data available

**Polatuzumab vedotin:**

- **Toxicity to fish**: LC50 (Danio rerio (zebra fish)): > 100 mg/l
  - End point: mortality
  - Exposure time: 96 h
  - Method: OECD Test Guideline 203
  - GLP: yes
  - Remarks: nominal concentration
  - NOEC (Danio rerio (zebra fish)): 100 mg/l

---

10 / 16
End point: mortality
Exposure time: 96 h
Method: OECD Test Guideline 203
GLP: yes
Remarks: nominal concentration

**Toxicity to daphnia and other aquatic invertebrates**

**EC50 (Daphnia magna (Water flea)): > 100 mg/l**
End point: Immobilization
Exposure time: 48 h
Method: OECD Test Guideline 202
GLP: yes
Remarks: nominal concentration

**NOEC (Daphnia magna (Water flea)): 100 mg/l**
End point: Immobilization
Exposure time: 48 h
Method: OECD Test Guideline 202
GLP: yes
Remarks: nominal concentration

**Toxicity to algae/aquatic plants**

**ErC50 (Desmodesmus subspicatus (green algae)): > 100 mg/l**
Exposure time: 72 h
Method: OECD Test Guideline 201
GLP: yes
Remarks: nominal concentration

**EyC50 (Desmodesmus subspicatus (green algae)): > 100 mg/l**
Exposure time: 72 h
Method: OECD Test Guideline 201
GLP: yes
Remarks: nominal concentration

**NOEC (Desmodesmus subspicatus (green algae)): 100 mg/l**
Exposure time: 72 h
Method: OECD Test Guideline 201
GLP: yes
Remarks: nominal concentration

**Toxicity to microorganisms**

**(activated sludge): 21.2 mg/l**
Exposure time: 28 d
Test Type: Respiration inhibition
Method: OECD Test Guideline 301F
GLP: yes
Remarks: Barely inhibitory on aerobic bacterial reproduction (activated sludge)

**Persistence and degradability**

**Components:**

**Polatuzumab vedotin:**

Biodegradability: aerobic
Inoculum: activated sludge
Concentration: 21.2 mg/l
Theoretical oxygen demand
Result: Readily biodegradable.
Biodegradation: 77 %
Exposure time: 28 d
Method: OECD Test Guideline 301F
GLP: yes

Physico-chemical removability: Method: OECD Test Guideline 301F
Remarks: Not abiotically degradable

Bioaccumulative potential

Components:

.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:
Partition coefficient: n-octanol/water: log Pow: -3.7 (68 °F / 20 °C)

Polatuzumab vedotin:
Partition coefficient: n-octanol/water: Remarks: No data available

Mobility in soil
No data available

Other adverse effects

Product:
Ozone-Depletion Potential: Regulation: 40 CFR Protection of Environment; Part 82 Protection of Stratospheric Ozone - CAA Section 602 Class I Substances
Remarks: This product neither contains, nor was manufactured with a Class I or Class II ODS as defined by the U.S. Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A + B).

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods
Waste from residues: Do not contaminate ponds, waterways or ditches with chemical or used container.
Send to a licensed waste management company.

Contaminated packaging: Empty remaining contents.
Dispose of as unused product.
Empty containers should be taken to an approved waste handling site for recycling or disposal.
Do not re-use empty containers.

SECTION 14. TRANSPORT INFORMATION

International Regulations
UNRTDG
SAFETY DATA SHEET

POLIVY(R) Vials (30 mg & 140 mg)

Version 2.0
Revision Date: 11-25-2022
Date of last issue: 01-23-2020
Date of first issue: 06-10-2017

UN number : UN 3249
Proper shipping name : MEDICINE, SOLID, TOXIC, N.O.S.
Class : 6.1
Packing group : II
Labels : 6.1

IATA-DGR
UN/ID No. : UN 3249
Proper shipping name : Medicine, solid, toxic, n.o.s.
Class : 6.1
Packing group : II
Labels : Toxic
Packing instruction (cargo aircraft) : 676
Packing instruction (passenger aircraft) : 669

IMDG-Code
UN number : UN 3249
Proper shipping name : MEDICINE, SOLID, TOXIC, N.O.S.
Class : 6.1
Packing group : II
Labels : 6.1
EmS Code : F-A, S-A
Marine pollutant : no

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not applicable

Domestic regulation

49 CFR
UN/ID/NA number : UN 3249
Proper shipping name : Medicine, solid, toxic, n.o.s.
Class : 6.1
Packing group : II
Labels : TOXIC
ERG Code : 151
Marine pollutant : no

Special precautions for user
Remarks : No data available

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

SECTION 15. REGULATORY INFORMATION

CERCLA Reportable Quantity
This material does not contain any components with a CERCLA RQ.

SARA 304 Extremely Hazardous Substances Reportable Quantity
This material does not contain any components with a section 304 EHS RQ.
SAFETY DATA SHEET

POLIVY(R) Vials (30 mg & 140 mg)

Version 2.0
Revision Date: 11-25-2022
Date of last issue: 01-23-2020
Date of first issue: 06-10-2017

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity
This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards
- Combustible dust
- Acute toxicity (any route of exposure)
- Germ cell mutagenicity
- Reproductive toxicity

SARA 313
This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

Clean Air Act
This product neither contains, nor was manufactured with a Class I or Class II ODS as defined by the U.S. Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A + B).
This product does not contain any hazardous air pollutants (HAP), as defined by the U.S. Clean Air Act Section 112 (40 CFR 61).
This product does not contain any chemicals listed under the U.S. Clean Air Act Section 112(r) for Accidental Release Prevention (40 CFR 68.130, Subpart F).
This product does not contain any chemicals listed under the U.S. Clean Air Act Section 111 SOCMI Intermediate or Final VOC's (40 CFR 60.489).

Clean Water Act
This product does not contain any Hazardous Substances listed under the U.S. Clean Water Act, Section 311, Table 116.4A.
This product does not contain any Hazardous Chemicals listed under the U.S. Clean Water Act, Section 311, Table 117.3.
This product does not contain any toxic pollutants listed under the U.S. Clean Water Act Section 307
This product does not contain any priority pollutants related to the U.S. Clean Water Act

US State Regulations

Massachusetts Right To Know
- .alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl 57-50-1

Pennsylvania Right To Know
- .alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl 57-50-1
- Polatuzumab vedotin 1313206-42-6

Maine Chemicals of High Concern
Product does not contain any listed chemicals

Vermont Chemicals of High Concern
Product does not contain any listed chemicals

Washington Chemicals of High Concern
Product does not contain any listed chemicals

California Permissible Exposure Limits for Chemical Contaminants
- .alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl 57-50-1

The ingredients of this product are reported in the following inventories:

AIIC : Not in compliance with the inventory

DSL : This product contains the following components that are not on the Canadian DSL nor NDSL.
SAFETY DATA SHEET

POLIVY(R) Vials (30 mg & 140 mg)

Polatuzumab vedotin

NZIoC : Not in compliance with the inventory
ENCS : Not in compliance with the inventory
ISHL : Not in compliance with the inventory
KECI : Not in compliance with the inventory
PICCS : Not in compliance with the inventory
IECSC : Not in compliance with the inventory
TCSI : Product contains substance(s) not listed on TSCA inventory.
TECI : Not in compliance with the inventory

TSCA list
No substances are subject to a Significant New Use Rule.
No substances are subject to TSCA 12(b) export notification requirements.

SECTION 16. OTHER INFORMATION

NFPA 704:

HMIS® IV:

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)
NIOSH REL : USA. NIOSH Recommended Exposure Limits
OSHA P0 : USA. Table Z-1-A Limits for Air Contaminants (1989 vacated)
SAFETY DATA SHEET

POLIVY(R) Vials (30 mg & 140 mg)

Version: 2.0
Revision Date: 11-25-2022
Date of last issue: 01-23-2020
Date of first issue: 06-10-2017

Revision Date: 11-25-2022

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials or in any process, unless specified in the text.

US / Z8 / 2104